These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 19035792

  • 1. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
    Bamborough P, Drewry D, Harper G, Smith GK, Schneider K.
    J Med Chem; 2008 Dec 25; 51(24):7898-914. PubMed ID: 19035792
    [Abstract] [Full Text] [Related]

  • 2. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F, Ardini E, Avanzi N, Casale E, Cervi G, D'Anello M, Donati D, Faiardi D, Ferguson RD, Fogliatto G, Galvani A, Marsiglio A, Mirizzi DG, Montemartini M, Orrenius C, Papeo G, Piutti C, Salom B, Felder ER.
    Bioorg Med Chem; 2013 Dec 01; 21(23):7364-80. PubMed ID: 24139169
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
    Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S, Schwaller J.
    Cancer Res; 2007 Jul 15; 67(14):6916-24. PubMed ID: 17638903
    [Abstract] [Full Text] [Related]

  • 5. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM.
    Proteins; 2007 Mar 01; 66(4):912-29. PubMed ID: 17173284
    [Abstract] [Full Text] [Related]

  • 6. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
    López-Ramos M, Prudent R, Moucadel V, Sautel CF, Barette C, Lafanechère L, Mouawad L, Grierson D, Schmidt F, Florent JC, Filippakopoulos P, Bullock AN, Knapp S, Reiser JB, Cochet C.
    FASEB J; 2010 Sep 01; 24(9):3171-85. PubMed ID: 20400536
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW, Möbitz H, Fabbro D.
    Curr Opin Cell Biol; 2009 Apr 01; 21(2):280-7. PubMed ID: 19208462
    [Abstract] [Full Text] [Related]

  • 9. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
    Packard GK, Papa P, Riggs JR, Erdman P, Tehrani L, Robinson D, Harris R, Shevlin G, Perrin-Ninkovic S, Hilgraf R, McCarrick MA, Tran T, Fleming Y, Bai A, Richardson S, Katz J, Tang Y, Leisten J, Moghaddam M, Cathers B, Zhu D, Sakata S.
    Bioorg Med Chem Lett; 2012 Jan 01; 22(1):747-52. PubMed ID: 22137342
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CHI's Fourth Annual Drug Discovery Chemistry Conference. Kinase inhibitor chemistry: charting the chemical space. 7-8 April 2009, San Diego, CA, USA.
    Seneci P.
    IDrugs; 2009 Jun 01; 12(6):358-62. PubMed ID: 19517315
    [No Abstract] [Full Text] [Related]

  • 13. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
    Annis DA, Nazef N, Chuang CC, Scott MP, Nash HM.
    J Am Chem Soc; 2004 Dec 01; 126(47):15495-503. PubMed ID: 15563178
    [Abstract] [Full Text] [Related]

  • 14. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ.
    Biochem J; 2013 Apr 15; 451(2):313-28. PubMed ID: 23398362
    [Abstract] [Full Text] [Related]

  • 15. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T, Kaptein A, de Wilde S, van der Heijden R, van Someren R, Demont D, Schultz-Fademrecht C, Versteegh J, van Zeeland M, Seegers N, Kazemier B, van de Kar B, van Hoek M, de Roos J, Klop H, Smeets R, Hofstra C, Hornberg J, Oubrie A.
    Bioorg Med Chem Lett; 2011 Jun 15; 21(12):3818-22. PubMed ID: 21565500
    [Abstract] [Full Text] [Related]

  • 16. A priori inference of cross reactivity for drug-targeted kinases.
    Fernandez A, Maddipati S.
    J Med Chem; 2006 Jun 01; 49(11):3092-100. PubMed ID: 16722629
    [Abstract] [Full Text] [Related]

  • 17. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
    Wu B, Wang HL, Cee VJ, Lanman BA, Nixey T, Pettus L, Reed AB, Wurz RP, Guerrero N, Sastri C, Winston J, Lipford JR, Lee MR, Mohr C, Andrews KL, Tasker AS.
    Bioorg Med Chem Lett; 2015 Feb 15; 25(4):775-80. PubMed ID: 25616902
    [Abstract] [Full Text] [Related]

  • 18. Structure-based design of low-nanomolar PIM kinase inhibitors.
    Ishchenko A, Zhang L, Le Brazidec JY, Fan J, Chong JH, Hingway A, Raditsis A, Singh L, Elenbaas B, Hong VS, Marcotte D, Silvian L, Enyedy I, Chao J.
    Bioorg Med Chem Lett; 2015 Feb 01; 25(3):474-80. PubMed ID: 25575657
    [Abstract] [Full Text] [Related]

  • 19. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
    Tsuhako AL, Brown DS, Koltun ES, Aay N, Arcalas A, Chan V, Du H, Engst S, Franzini M, Galan A, Huang P, Johnston S, Kane B, Kim MH, Laird AD, Lin R, Mock L, Ngan I, Pack M, Stott G, Stout TJ, Yu P, Zaharia C, Zhang W, Zhou P, Nuss JM, Kearney PC, Xu W.
    Bioorg Med Chem Lett; 2012 Jun 01; 22(11):3732-8. PubMed ID: 22542012
    [Abstract] [Full Text] [Related]

  • 20. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.
    Cancilla MT, He MM, Viswanathan N, Simmons RL, Taylor M, Fung AD, Cao K, Erlanson DA.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):3978-81. PubMed ID: 18579375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.